SMITHS GROUP SERVICES CORPORATION for SMITHS GROUP SERVICES CORPORATION
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
General trade discussions including Section 301 and Section 232 tariffs. Issues related to the United States-Mexico-Canada Agreement (P.L.116-113).
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA CEGLIA | — |
Defense DEF
Issues related to CBRNE (Chemical, Biological, Radiological, Nuclear and Explosives) technology, detection solutions for the Department of Defense, and Navy RDT&E and Ship Equipment; FY2022 Department of Defense Appropriations Act; FY2022 National Defense Authorization Act.
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA CEGLIA | — |
| KEVIN SCHMIDT | — |
Budget/Appropriations BUD
Funding for aviation security and homeland security technologies. FY2022 Department of Homeland Security Appropriations Act; Transportation Security Administration (TSA) funding. FY2022 Department of Defense Appropriations Act; Chemical Bio Funding; Navy RDT&E. FY2022 Commerce, Justice, Science, and Related Agencies Appropriations Act; Opioid Funding. FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act; Reimbursement for Medical Devices. FY2022 National Defense Authorization Act. H.R.748, CARES Act (P.L.116-136) implementation. H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation. H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA CEGLIA | — |
| KEVIN SCHMIDT | — |
Environment/Superfund ENV
Issues related to climate change and emissions technologies. Issues related to mechanical seals emissions technologies and energy infrastructure. Issues related to PFAS. Issues related to hydro power and nuclear power. General discussions regarding technical expertise in sealing device technology and emissions reductions.
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA CEGLIA | — |
Aviation/Airlines/Airports AVI
Aviation security solutions and detection technologies for the Transportation Security Administration (TSA). FY2021/FY2022 DHS Authorization. Issues related to the Funding for Aviation Screeners and Threat Elimination Restoration (FASTER) Act (H.R.1813); aviation security fees.
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN SCHMIDT | — |
Homeland Security HOM
Aviation security solutions and detection technologies for the Transportation Security Administration (TSA), Department of Homeland Security (DHS), U.S. Customs and Border Protection (CBP) and the Domestic Nuclear Detection Office (DNDO). CBRNE (Chemical, Biological, Radiological, Nuclear and Explosives) technology and other border security solutions. FY2022 Department of Homeland Security Appropriations Act; Transportation Security Administration (TSA) funding. Issues related to the Funding for Aviation Screeners and Threat Elimination Restoration (FASTER) Act (H.R.1813); aviation security fees.
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN SCHMIDT | — |
Medical/Disease Research/Clinical Labs MED
Policies and issues related to medical device technology, including: patient infusion therapy, Medicare reimbursement for opioid alternative treatments, federal COVID response, and medical supply chain shortages; H.R.748, CARES Act (P.L.116-136); S.987, CARA 3.0 Act of 2021; S.586/H.R.3259, NOPAIN Act.
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA CEGLIA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.